检索结果 - Trivikram Rajkhowa

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells

    The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells 由 Emily Chang, Sudipto Ganguly, Trivikram Rajkhowa, Christopher D. Gocke, Mark J. Levis, Helmut König

    出版 2015
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML 由 Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark J. Levis

    出版 2009
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

    Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants 由 Allison Galanis, Hayley Ma, Trivikram Rajkhowa, Abhijit Ramachandran, Donald Small, Jorge E. Cortés, Mark J. Levis

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor 由 Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Raman, Bao Nguyen, Donald Small, Mark J. Levis

    出版 2016
    获取全文 获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    A potential therapeutic target for FLT3-ITD AML: PIM1 kinase

    A potential therapeutic target for FLT3-ITD AML: PIM1 kinase 由 Amir T. Fathi, Omotayo Arowojolu, Ian Swinnen, Takashi Sato, Trivikram Rajkhowa, Donald Small, Fredrik Marmsater, John Robinson, Stefan Groß, Matthew Martinson, Shelley Allen, Nicholas C. Kallan, Mark J. Levis

    出版 2011
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

    Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome 由 Paolo Strati, Hagop M. Kantarjian, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan M. Kadia, Zeev Estrov, Guillermo Garcia‐Manero, Marina Konopleva, Trivikram Rajkhowa, Menda Durand, Michael Andreeff, Mark J. Levis, Jorge E. Cortés

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML 由 Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia 由 Richard T. Maziarz, Mark J. Levis, Mrinal M. Patnaik, Bart L. Scott, Sanjay Mohan, Abhinav Deol, Scott D. Rowley, Dennis Dong Hwan Kim, Daniela Hernandez, Trivikram Rajkhowa, Kelly Haines, Gaetano Bonifacio, Patrice Rine, Das Purkayastha, Hugo F. Fernández

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia

    A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia 由 Mark J. Levis, Alexander E. Perl, Gary J. Schiller, Amir T. Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Trivikram Rajkhowa, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, K.Y. Cheung, Michael R. Kurman, Catherine C. Smith

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation 由 Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia‐Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Tapan M. Kadia, Sara Dellasala, Michael Andreeff, Jorge E. Cortés, Hagop M. Kantarjian, Mark J. Levis

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia

    Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia 由 Yi‐Bin Chen, Shuli Li, Andrew A. Lane, Christine Connolly, Candice Del Rio, Betsy Valles, Morgan Curtis, Karen K. Ballen, Corey Cutler, Bimalangshu R. Dey, Areej El‐Jawahri, Amir T. Fathi, Vincent T. Ho, Amy Joyce, Steven L. McAfee, Michelle A. Rudek, Trivikram Rajkhowa, Sigitas Verselis, Joseph H. Antin, Thomas R. Spitzer, Mark J. Levis, Robert J. Soiffer

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: